|
The Real Effect of Prostate Cancer Treatment: EUPROMS First-Ever Prostate Patient-Driven Quality of Life Study
|
André Deschamps, MD
|
André Deschamps presented a study assessing the quality of life of patients after being treated for prostate cancer. The study involved a 20-minute online survey intended for patients with prostate cancer who received treatment in Europe. It is an observational one-arm study, aiming to examine the quality of life of prostate cancer patients in Europe. The study used validated quality of life questionnaires
|
|
|
|
|
Treatment of Recurrent Lymph Node Metastatic Prostate Cancer - Surgery Is the Best Option
|
Steven Joniau, MD, PhD
|
Steven Joniau discussed the role of surgery as the best option for men with treatment of recurrent lymph node metastatic prostate cancer at the 2020 European Association of Urology (EAU) Virtual Meeting. Dr. Joniau notes that the location of relapse is important in relation to treatments received. Lymph node recurrence may be highly variable, with recent data suggesting that 44% of recurrences are distal to the common iliac bifurcation, 28.5% in the retroperitoneum, 15.5% in the common iliac/pre-sacral region, and 3% perirectal.
|
|
|
|
|
|
|
|
|
|
|
|
STATE-OF-THE-INDUSTRY VIDEOS BY LEADING UROLOGY EXPERTS
|
|
|
|
|
|
|
Financial Toxicity and Quality of Life: Understanding and Improving Patient-Centered Outcomes in Genitourinary Malignancies
|
David F. Penson, MD, MPH, MMHC
David Penson provides insights on his keynote lecture from ASCO GU 2020 in this conversation with Alicia Morgans. He focuses on recognizing that methods of effectively measuring a patient’s quality of life are not easy to define
|
|
|
|
|
|
|
|
|
Movember Session: Outcomes Research – IRONMAN Project |
Alicia Morgans, MD, MPH, Ian Davis, MB, BS, Ph.D., FRACP, FAChPM
Alicia Morgans and Ian Davis presented an update on the IRONMAN study, an International Registry for Men with Advanced Prostate Cancer at the Advanced Prostate Cancer Consensus Conference. |
|
|
|
|
|
|
Quality of Life During Treatment with Chemohormonal Therapy |
Alicia Morgans, MD, MPH |
Alicia Morgans and Charles Ryan discuss the quality of life between patients with metastatic hormone-sensitive prostate cancer who were treated with ADT+docetaxel and those who were treated with ADT alone. The importance of the study was to understand how different treatments actually affected the individuals receiving them. |
|
|
|
|
|
|
|
|
|
|
The Clinical Implications and Health-related Quality of Life Benefits: Reviewing the CARD Study Results in Men with mCRPC
|
Neal Shore, MD, FACS
Alicia Morgans and Neal Shore discuss the clinical implications of the CARD study, a phase 4 study demonstrating the first third-line treatment for metastatic castration-resistant prostate cancer, that prolonged overall survival with cabazitaxel as compared to treatment with a second AR targeted agent in men who had docetaxel and the alternative AR targeted agent in their prior treatment history.
|
|
|
|
|
|
|
|
|
Patients' Quality of Life in Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treatment Decisions |
Alicia Morgans, MD, MPH
Alicia Morgans discusses the role of integrating patients in treatment decisions by incorporating quality of life, in particular when there are multiple treatments available with similar efficacy. |
|
|
|
|
|
|
|
|
The Management of Fatigue, Cognition, and Dementia in Prostate Cancer Patients |
Charles Ryan, MD |
Charles Ryan presents the management of fatigue and cognitive changes induced by androgen deprivation therapy (ADT). Dr. Ryan discusses the association between ADT and dementia, and also how combining ADT with abiraterone and prednisone can significantly improve fatigue in patients. |
|
|
|
|
|
|
|
|
|
|
|
|